CHF90.7m market cap
CHF8.1 last close
Polyphor is a development stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a CXCR4 inhibitor currently in Phase III for breast cancer. Data are expected in 2021. It plans to start its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in CF patients by the year end.
Investment summary
Polyphor is a development-stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor currently in a randomised-controlled Phase III trial in 407 previously treated human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer patients. Objective response rate (ORR) data from the trial are expected in Q221 and could allow for an accelerated approval filing in the US. Additionally, it plans to start its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in cystic fibrosis (CF) patients by the end of the year.
Y/E Dec |
Revenue (CHFm) |
EBITDA (CHFm) |
PBT (CHFm) |
EPS (CHFc) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 6.5 | (41.6) | (45.6) | (484.0) | N/A | N/A |
| 2019A | 0.0 | (64.9) | (64.2) | (581.0) | N/A | N/A |
| 2020E | 13.7 | (44.9) | (45.1) | (404.0) | N/A | N/A |
| 2021E | 0.0 | (48.6) | (48.8) | (428.0) | N/A | N/A |
Industry outlook
According to the National Cancer Institute, 78% of the estimated 276,480 new cases of breast cancer every year are HER2 negative. For those who are HER2 negative and hormone-receptor positive (68% of breast cancers), chemotherapy remains the standard of care in over 90% of cases once past front-line therapy.
Last updated on 01/12/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (CHFm) | 25.6 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Gökhan Batur | CEO |
| Hernan Levett | CFO |
| Martin Jakobovic | Business planning analyst |
Content on Polyphor
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma